BioSpace News Archive

Mosaic ImmunoEngineering Inc., (the “Company” or “Mosaic”) (OTC PINK:PTSCD), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, announced today that The Financial Industry Regulatory Authority, Inc., (FINRA), has approved a change in the Company’s stock symbol trading on the OTC Markets Pink.

AIDS Healthcare Foundation welcomed and praised an advisory opinion issued earlier by the Office of the General Counsel for the United States Health and Human Services Department which concluded that drug manufacturers are required to deliver discounts under the 340B Drug Pricing Program on covered outpatient drugs when contract pharmacies are acting as agents of 340B covered entities.

The FDA is alerting pet owners and veterinary professionals about certain Sportmix pet food products manufactured by Midwestern Pet Foods, Inc. that may contain potentially fatal levels of aflatoxin.

– Sulanda ® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS in all subgroups of non-pancreatic NET patients with an acceptable risk/benefit ratio – – ~400-strong oncology commercial team in place to bring Sulanda ® to patients in China – HONG KONG and FLORHAM PARK, N.J., Dec. 30,

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Biotech Showcase™ Digital 2021. The conference is taking place online between January 11-15 and will feature prerecorded sessions of company presentations. Spiro Rombotis, President & Chief Executive Office

- Incyte and Cellenkos will evaluate the combination of ruxolitinib (Jakafi ® ) and CK0804, cord blood-derived T-regulatory cells, in patients with myelofibrosis - Incyte has an exclusive option to acquire sole rights to CK0804

Bactiguard has received an initial order for coating concentrate from Well Lead Medical (Well Lead) in China . The order will be delivered promptly and generate license revenues in the fourth quarter 2020 of approximately SEK 9 million. In parallel with the marketing and sales of Bactiguard’s BIP Foley urinary catheters in the C

Olympus Corporation today announced that it has finalized the acquisition of Veran Medical Technologies, Inc. (VMT), a leading provider of advanced medical devices specializing in interventional pulmonology, fol

Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 PM ET

Innovative, novel approach to treat and protect against SARS-CoV-2 using thermoresponsive virus-targeting nanoparticles as an inhalation medicine Program includes development of a heat-sensitive fluorescent SARS-CoV-2 detection assay through patient mucosal sampling